Myasthenia and risk of cancer: A population-based case-control study

European Journal of Neurology

Volumn 21, Issue 5, 2014, Pages 773-778

  Pedersen, E G ^a   Pottegard A ^b   Hallas, J ^b   Friis, S ^c   Hansen, K ^d   Jensen, P E H ^d   Gaist, D ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

Author keywords

Case control studies; Epidemiology; Myasthenia; Oncology

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDOSTIGMINE; TACROLIMUS;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MYASTHENIA; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; THYMUS CANCER; AUTOIMMUNE DISEASES; CASE CONTROL STUDY; EPIDEMIOLOGY; HEALTH CARE PLANNING; MIDDLE AGED; NEUROMUSCULAR DISEASES; REGISTER; RETROSPECTIVE STUDY; RISK; THYMUS NEOPLASMS;

ADULT; AGED; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; COMMUNITY HEALTH PLANNING; DENMARK; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROMUSCULAR DISEASES; ODDS RATIO; REGISTRIES; RETROSPECTIVE STUDIES; THYMUS NEOPLASMS;

EID: 84897959182     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12383     Document Type: Article

References (28)

1. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
2. Dalakas MC. Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 2013; 12: 936-941.
3. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Late-onset myasthenia not on the increase: a nationwide register study in Denmark, 1996-2009. Eur J Neurol 2013; 20: 309-314.
4. Evoli A, Batocchi AP, Tonali P, Marciano M. Risk of cancer in patients with myasthenia gravis. Ann N Y Acad Sci 1998; 841: 742-745.
5. Citterio A, Beghi E, Millul A, et al. Risk factors for tumor occurrence in patients with myasthenia gravis. J Neurol 2009; 256: 1221-1227.
6. Owe JF, Cvancarova M, Romi F, Gilhus NE. Extrathymic malignancies in thymoma patients with and without myasthenia gravis. J Neurol Sci 2010; 290: 66-69.
7. Ehrenfeld M, Abu-Shakra M, Buskila D, Shoenfeld Y. The dual association between lymphoma and autoimmunity. Blood Cells Mol Dis 2001; 27: 750-756.
8. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54: 692-701.
9. IARC. A Review of Human Carcinogens. Part A: Pharmaceuticals, Vol. 100A. Lyon: International Agency for Research on Cancer, 2008: 319-331.
10. Liu CJ, Chang YS, Teng CJ, et al. Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 2012; 19: 746-751.
11. Thygesen LC, Ersbøll AK. Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 2011; 39(7 Suppl): 8-10.
12. Gaist D, Andersen L, Hallas J, Toft Sørensen H, Schrøder HD, Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer 2013; 108: 715-720.
13. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011; 39(7 Suppl): 22-25.
14. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39(7 Suppl): 30-33.
15. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39(7 Suppl): 38-41.
16. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39(7 Suppl): 42-45.
17. Bjerregaard B, Larsen OB. The Danish Pathology Register. Scand J Public Health 2011; 39(7 Suppl): 72-74.
18. Pedersen EG, Hallas J, Hansen K, Jensen PE, Gaist D. Identifying patients with myasthenia for epidemiological research by linkage of automated registers. Neuroepidemiology 2011; 37: 120-128.
19. Pedersen EG, Pottegård A, Hallas J, et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur J Neurol 2013; 20: 942-948.
20. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology, 3rd edn. Philadelphia, PA: Lippincott Williams and Wilkins, 2008: 124-125.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
22. Secretan B, Straif K, Baan R, et al. A review of human carcinogens - Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034.
23. Monden Y, Uyama T, Kimura S, Taniki T. Extrathymic malignancy in patients with myasthenia gravis. Eur J Cancer 1991; 27: 745-747.
24. Levin N, Abramsky O, Lossos A, et al. Extrathymic malignancies in patients with myasthenia gravis. J Neurol Sci 2005; 237: 39-43.
25. Wakata N, Sugimoto H, Nomoto N, et al. Extrathymic tumors in patients with myasthenia gravis: a 35-year retrospective study. Neurologist 2006; 12: 53-55.
26. Lai CH, Tseng HF. Nationwide population-based epidemiological study of myasthenia gravis in Taiwan. Neuroepidemiology 2010; 35: 66-71.
27. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
28. Engel PH, Sabroe S. Thymoma in Denmark. Ugeskr Laeger 1996; 159: 3156-3159 [In Danish].